Recovery Research

What is BPC-157? A Research Primer

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide derived from a protective sequence within human gastric juice protein — studied across an unusually broad range of tissue repair, angiogenic, gastrointestinal, and neuroprotective research models. May 2, 2026Research Primer14 min read

Origins and Discovery

BPC-157 (sequence: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) is a synthetic 15-amino acid peptide derived from a partial sequence of Body Protection Compound — a protein isolated from human gastric juice by the research group of Predrag Sikiric at the University of Zagreb, Croatia, beginning in the early 1990s. The parent protein was identified through its protective effects on gastric mucosa, and BPC-157 represents the biologically active partial sequence responsible for those effects.

BPC-157 is stable in gastric acid (hence the designation "stable gastric pentadecapeptide" in some literature) and shows activity via both oral and parenteral routes — an unusual property among research peptides that are typically degraded in the gastrointestinal tract. This stability makes BPC-157 one of the few peptides that has been studied with oral administration models in addition to subcutaneous and intragastric routes.

SequenceGly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val Molecular Weight1,419.5 Da Amino Acids15 (pentadecapeptide) Source OrganismHuman gastric juice (parent protein) Route StabilityStable in gastric acid; oral and parenteral activity Research ModelsRodent (primary); in vitro cell models

Research Domains

Tendon & Ligament

Accelerated healing in Achilles tendon transection, MCL, and rotator cuff models. Upregulates tendon-specific growth factors.

Gastrointestinal

Mucosal protection in ulcer, IBD, and gut fistula models. Inhibits gastric acid through novel non-receptor mechanisms.

Angiogenesis

Promotes VEGF expression and new vessel formation. Accelerates wound bed vascularisation in ischemic tissue models.

Bone & Cartilage

Enhanced fracture healing and growth plate repair in rodent models. Modulates osteoblast and chondrocyte activity.

CNS & Neuroprotection

Attenuates dopamine system disruption. Studied in models of TBI, spinal cord injury, and nerve crush injury.

Muscle

Accelerated recovery from crush injury. Counteracts corticosteroid-induced muscle weakness in rodent models.

Mechanism of Action

BPC-157 does not act through a single well-characterized receptor like most research peptides. Its mechanisms appear to be pleiotropic — operating through multiple molecular targets simultaneously, which accounts for both its broad tissue activity and the challenges in definitively characterizing its primary mode of action. The most consistently documented mechanisms include:

Nitric Oxide System Modulation

BPC-157 modulates nitric oxide (NO) signaling in a context-dependent manner. In models of ischemia and vascular injury, BPC-157 appears to upregulate endothelial nitric oxide synthase (eNOS) activity, promoting vasodilation and improving local blood flow. Critically, this NO-mediated effect appears to operate through a pathway distinct from conventional NOS substrates — BPC-157 has been shown to maintain its protective effects even in the presence of NOS inhibitors like L-NAME, suggesting parallel mechanisms beyond simple NOS activation.

Growth Factor Upregulation

BPC-157 consistently upregulates VEGF (vascular endothelial growth factor) and EGF (epidermal growth factor) receptor expression in healing tissues. The VEGF upregulation is particularly relevant to its angiogenic and wound-healing effects: by promoting new blood vessel ingrowth into healing tissue, BPC-157 accelerates the delivery of oxygen and nutrients essential for repair. This mechanism is well-documented in tendon, gut, and skin wound healing models.

FAK and Src Signaling

Research by Sikiric's group and independent investigators has identified focal adhesion kinase (FAK) and Src kinase pathways as key mediators of BPC-157's pro-healing effects. FAK is a central coordinator of cell migration, proliferation, and survival — all essential processes in tissue repair. BPC-157 appears to activate FAK-paxillin signaling in fibroblasts and tenocytes, promoting their migration into damaged tissue and accelerating matrix deposition.

Tendon and Connective Tissue Research

BPC-157's most replicated preclinical findings concern tendon healing. In Achilles tendon transection models in rats — one of the most standardized musculoskeletal research protocols — BPC-157 administered systemically (intraperitoneally or subcutaneously) or locally (at the wound site) produces significantly faster macroscopic healing, superior histological tendon organization, and improved biomechanical properties (tensile strength, elastic modulus) compared to controls. Effect sizes in these models have been consistent across multiple independent groups.

Ligament healing research has shown similar findings in MCL (medial collateral ligament) injury models. Perhaps most notable are studies in which BPC-157 counteracted corticosteroid-induced tendon and bone damage — suggesting potential utility in research contexts examining corticosteroid side effects on connective tissue.

Gastrointestinal Research

Given BPC-157's gastric origin, its GI research is among the most extensive. It has demonstrated protective effects in models of: NSAIDs-induced gastric ulceration, alcohol-induced gastric and intestinal injury, inflammatory bowel disease (via cytoprotective and anti-inflammatory effects on intestinal mucosa), bowel anastomosis healing, and intestinal fistula closure. The latter — fistula healing — is a particularly challenging clinical problem, and BPC-157's consistent pro-healing effects in this model have attracted attention from gastroenterological research groups outside Sikiric's institution.

CNS and Dopamine System Research

A less widely known but substantial body of research concerns BPC-157's effects on the central nervous system — particularly the dopaminergic system. Studies have examined BPC-157 in models of dopamine dysregulation including: antipsychotic-induced tardive dyskinesia, haloperidol-induced catalepsy, amphetamine-induced hyperactivity, and dopamine receptor disruption. BPC-157 consistently modulates dopaminergic tone toward normalization — reducing excess dopamine activity and partially rescuing dopamine depletion — through mechanisms that appear to involve dopamine receptor upregulation and dopamine transporter modulation.

In spinal cord and peripheral nerve injury models, BPC-157 has been shown to improve functional recovery and axonal regrowth, likely through its angiogenic and neurotrophic signaling effects.

Evidence Limitation Note

The vast majority of BPC-157 research originates from or is associated with a single research group at the University of Zagreb. While the findings are internally consistent and many have been replicated within that group across large numbers of experiments, independent replication by other research institutions is limited. This is an important caveat for interpreting the literature. The compound's lack of an identified primary receptor has also made it difficult to construct the mechanistic framework needed to accelerate clinical development.

Administration Routes and Stability

BPC-157 has been studied via subcutaneous, intraperitoneal, intragastric (oral), topical, and local injection routes. Most rodent research uses intraperitoneally or subcutaneously administered doses of 1–10 µg/kg, with some studies using ng/kg doses demonstrating activity. The compound's gastric acid stability — attributed to its proline-rich sequence — is genuine: it has been shown to retain activity when administered orally in rodent models, though bioavailability data for oral administration in higher species is limited. Lyophilized BPC-157 is stable at −20°C for 24+ months; reconstituted solutions should be used within 4 weeks when stored at 2–8°C.

Research Use Only — Disclaimer This document is prepared for laboratory and research reference purposes only. BPC-157 is not FDA-approved for any human therapeutic use. All findings referenced are from preclinical rodent models or in vitro studies. No Phase II or III human clinical trials have been completed as of publication. This content does not constitute medical advice. Researchers must comply with all applicable institutional and jurisdictional regulations.

References

1. Sikiric P, et al. "The influence of a novel pentadecapeptide, BPC 157, on N(G)-nitro-L-arginine methylester and L-arginine effects on stomach mucosa integrity and blood pressure." Eur J Pharmacol. 1997;332(1):23–33.
2. Chang CH, et al. "The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration." J Appl Physiol. 2011;110(3):774–780.
3. Gwyer D, et al. "Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing." Cell Tissue Res. 2019;377(2):153–159.
4. Sikiric P, et al. "Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications." Curr Neuropharmacol. 2016;14(8):857–865.
5. Pevec D, et al. "Impact of pentadecapeptide BPC 157 on muscle healing impaired by systemic corticosteroid application." Med Sci Monit. 2010;16(3):BR81–88.
6. Sikiric P, et al. "Stable gastric pentadecapeptide BPC 157 as a therapy for the disable myocardial infarction in rats." Curr Pharm Des. 2018;24(26):3000–3008.